Merck, Moderna therapy cuts melanoma recurrence or death risk 42% in Phase 3 trial

Bitget2026/10/22 19:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Merck and Moderna reported positive Phase 3 INTerpath-001 results for investigational intismeran autogene combined with Keytruda in completely resected stage IIB-IV melanoma.
The combination significantly reduced recurrence or death and distant metastasis or death compared with Keytruda alone.
Results will be presented for the first time at the ESMO Congress 2026 Presidential Symposium.
No new safety signals emerged; overall survival data remain immature, with a favorable trend observed.
The partners are engaging with regulatory authorities based on the findings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261022568161) on October 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Merck, Moderna therapy cuts melanoma recurrence or death risk 42% in Phase 3 trial

You may also like

Crypto prices